The company will work with USC researchers in a year-long study aimed at assessing the clinical utility of EntroGen's PCR-based liquid biopsy test for EGFR mutations.
The test is a targeted next-gen sequencing assay that uses Illumina's MiniSeq, MiSeq, and NextSeq platforms to detect somatic mutations in BRCA1 and BRCA2.
EntroGen this week announced the availability of expanded colorectal cancer screening products.
Myriad Releases Interim PROCEDE 500 Clinical Utility Trial Data for Prolaris
The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.